<DOC>
	<DOC>NCT00139074</DOC>
	<brief_summary>The primary purpose is to investigate whether the addition of sodium valproate will be superior to treatment with quetiapine (Seroquel) given as monotherapy for an additional 14 days in non-responding patients after a 14 day initial treatment period with quetiapine. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Patients suffering from a manic or mixed episode. Patients who have not provided personal informed consent, Known intolerance, hypersensitivity or lack of antimanic response to sodium valproate or quetiapine fumarate, Involuntary admittance/detainment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Bipolar I Disorder (DSM-IV 296.01, DSM-IV 296.4, DSM-IV 296.61)</keyword>
</DOC>